(IN BRIEF) GSK announced that the European Commission has approved Nucala (mepolizumab) as an add-on maintenance treatment for adults in the EU with uncontrolled COPD characterised by raised blood eosinophils who are already receiving inhaled triple therapy, making it the … Read the full press release
Posted in Business, Financial, Government, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Technology, United Kingdom
Tagged American Thoracic Society, blood eosinophils, COPD, CRSwNP, EGPA, emergency department visits, eosinophilic phenotype, European Commission, European Federation of Allergy and Airways Diseases Patients’ Associations, Exacerbations, GSK, GSK Expands Nucala’s European Indications with Landmark Approval for Uncontrolled COPD, GSK Strengthens Its Respiratory Portfolio as Nucala Receives EU Approval for Add-On COPD Treatment, HES, hospitalisations, IL-5, inhaled triple therapy, Kaivan Khavandi, MATINEE trial, mepolizumab, New England Journal of Medicine, Nucala, Phase III, respiratory medicine, Severe Asthma, Susanna Palkonen, type 2 inflammation
(IN BRIEF) GSK has received approval from China’s National Medical Products Administration for Nucala as an add-on maintenance therapy for adults with inadequately controlled COPD and elevated blood eosinophils. Supported by positive MATINEE and METREX phase III trial data, the … Read the full press release
Posted in Business, Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biologic therapy, blood eosinophil count, China Approves GSK’s Nucala to Reduce Exacerbations in Adults with COPD, China NMPA approval, Chronic obstructive pulmonary disease, COPD treatment, eosinophilic COPD, exacerbation reduction, GSK, IL-5 monoclonal antibody, Kaivan Khavandi, MATINEE trial, mepolizumab, METREX trial, Nucala, respiratory medicine
Tony Wood übernimmt im August 2022 die volle Verantwortung für die F&E von GSK Hal Barron wechselt im August 2022 vom CSO zu einem GSK Non-Executive Director mit zusätzlichen Verantwortlichkeiten zur Unterstützung von Forschung und Entwicklung (PRESSEMITTEILUNG) LONDON, 19-Jan-2022 — … Read the full press release
Posted in Healthcare, Management, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged Academy of Medical Sciences, Adrestia, Altius Institute, Altos Labs, biotechnologie, Blenrep, Board of the Rosalind Franklin Institute, Cabenuva, Chief Scientific Officer, CSO, Dr. Hal Barron, Emma Walmsley, Ernennung, F&E, Forschung und Entwicklung, Genome Research, Genomik, GlaxoSmithKline plc, GSK, Immunologie, Imperial College, Infektionskrankheiten, Jemperli, künstliche Intelligenz, maschinelles Lernen, Medikamente, Nucala, Onkologie, Pfizer, Royal Society of Biology, Royal Society of Chemistry, Tony Wood, UK National Genomics Board, University of Newcastle, Xevudy
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?